1. Present efficacy data on antiviral treatment of symptomatic congenital CMV disease

2. Discuss the safety risks of treatment of congenital CMV disease

3. Identify opportunities for further improvements in outcomes of congenital CMV infections


Session date: 
11/29/2018 - 12:00pm to 1:00pm CST
Chicago, IL 60637
United States
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Please login or create an account to proceed.
Speaker Name: 
David Kimberlin, MD